MFA
INDV icon

McClarren Financial Advisors’s Indivior Pharmaceuticals INDV Stock Holding History

McClarren Financial Advisors’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-86
Closed -$1K – 387
2023
Q4 		$1K Hold
86
– – ﹤0.01% 349
2023
Q3 		$1K Buy
+86
New +$1.96K ﹤0.01% 306

Other funds holding INDV

PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $19.4B AUM 16.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return

McClarren Financial Advisors's INDV Position: Q1 2024 in Review

McClarren Financial Advisors sold out of Indivior Pharmaceuticals (INDV) in Q1 2024, closing a stake of 86 shares — an estimated $1K sold.

McClarren Financial Advisors first reported a position in INDV in Q3 2023 and held it in 2 quarters. The position peaked at $1K in Q4 2023. 95 funds tracked by Wall St. Rank hold INDV as of Q1 2024.

  • McClarren Financial Advisors reported no remaining Indivior Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • McClarren Financial Advisors sold 86 Indivior Pharmaceuticals shares in Q1 2024, an estimated $1K.
  • McClarren Financial Advisors first reported a position in Indivior Pharmaceuticals in Q3 2023 and held it in 2 quarters.
  • McClarren Financial Advisors's Indivior Pharmaceuticals position peaked at $1K in Q4 2023.
  • 95 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q1 2024.

Based on McClarren Financial Advisors's 13F filing for Q1 2024, filed 3 May 2024.